Intuitive Surgical stock holds at $372 as da Vinci platform expands in robotic surgery
Published on 08/31/2026 at 16:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Intuitive Surgical Inc. (US46120E6023) stock is quoted at $372.60 on Nasdaq as of August 30, 2026, positioning the shares well below their 52-week high but in the context of steadily growing adoption of the company’s da Vinci robotic surgery platform.
Stock price and recent trading context
Market data compiled on August 30, 2026 show Intuitive Surgical stock closing the latest regular Nasdaq session at $372.60, up from $367.07 in the preceding session, with the day’s trading range spanning $366.74 to $373.40. As of the same date, the shares are measured against a 52-week high of $603.88, indicating that the current quote stands distinctly below the past-year peak even after the recent rebound. A separate market-data overview for Intuitive Surgical lists a current price of $372.60 and confirms the move from the prior close, underlining that investors are trading the name at a level that reflects both the latest earnings and expectations for continued procedure growth.
For investors, one practical point is the spread between the latest price and selected valuation markers. An earlier analyst objective of $500 places the August 30, 2026 close of $372.60 at a discount to that target, illustrating how the market is currently pricing Intuitive Surgical shares relative to certain forward-looking benchmarks. At the same time, equity ownership changes reported by institutional managers show that large holders have been actively adjusting their exposure to Intuitive Surgical, with some trimming positions and others increasing stakes in response to the evolving outlook for robotic surgery demand and valuation.
Earnings momentum and consensus backdrop
The most recent analyst consensus compiled in the same coverage cycle assigns Intuitive Surgical a “Moderate Buy” rating, together with a consensus price objective of $508.68. This implies that, at the August 30, 2026 closing price of $372.60, the shares are trading below the average target level, leaving a gap of more than $130 between the current market quote and where analysts collectively expect the stock to gravitate over their forecast horizon. That differential highlights how the market’s present risk-reward assessment contrasts with the earnings and procedure-growth trajectory that analysts are modeling for Intuitive Surgical.
In recent quarters, Intuitive Surgical has emphasized that the performance of its da Vinci platform is closely tied to procedure volume growth and installed-base expansion. Earnings updates in 2026 have focused on how rising numbers of minimally invasive surgeries performed with da Vinci systems support higher recurring revenue from instruments, accessories, and services. As procedure counts increase, the company has sought to maintain healthy operating margins by managing costs and investing in innovation, including the latest generation of the da Vinci system that adds enhanced feedback and workflow features for surgeons.
The consensus view reflected in recent market data is that Intuitive Surgical’s earnings profile benefits from the combination of recurring revenue and a large installed base of da Vinci systems across hospitals worldwide. With the shares trading well below the 52-week high of $603.88 and under the consensus price objective of $508.68 as of late August 2026, investors are weighing macro uncertainties and competitive dynamics against the company’s track record of converting procedure growth into higher revenue and profit.
Robotic surgery adoption and da Vinci platform
Intuitive Surgical’s core product is the da Vinci surgical system, a robotic-assisted platform designed for minimally invasive procedures across multiple specialties, including gynecology, urology, general surgery, and thoracic surgery. The system enables surgeons to operate through small incisions with instrument articulation that exceeds the range of motion of the human hand, while providing high-definition 3D visualization of the operative field. Over time, da Vinci systems have been deployed in thousands of hospitals globally, and more than 20 million procedures have been performed using the platform, underscoring its central role in the evolution of robotic-assisted surgery.
Within gynecology, da Vinci procedures encompass hysterectomy, pelvic organ prolapse surgery, myomectomy, and endometriosis resection, among other operations. Intuitive Surgical provides detailed patient-facing information that describes how da Vinci technology is used in these gynecologic procedures, emphasizing the potential benefits of smaller incisions, reduced blood loss, and shorter recovery times compared with conventional open surgery. This specialty mix matters for investors because gynecologic procedures contribute significantly to the overall volume of surgeries performed on the da Vinci platform and therefore to the instruments and accessories revenue that forms a recurring component of Intuitive Surgical’s business model.
Robotic surgery is also gaining scale in emerging and developing markets, which can expand Intuitive Surgical’s long-term addressable market. In Brazil, for example, recent reporting notes that there are roughly 180 da Vinci robotic systems installed nationwide, with around 40 deployed in public or philanthropic healthcare networks. The latest generation of the da Vinci platform, introduced in the United States in 2024 and subsequently in Europe, is expected to reach Brazilian hospitals in 2026, illustrating how newer system versions roll out across geographies and can drive replacement and upgrade cycles for Intuitive Surgical.
In parallel, coverage of robotic-assisted surgery highlights features of the newest da Vinci systems that integrate advanced capabilities such as tactile feedback and AI-driven assistance. The latest da Vinci iteration supports surgeons by providing real-time feedback on resistance and force, helping to improve safety in delicate operations. As these technological enhancements are adopted at scale, they have the potential to increase procedure efficiency and broaden the range of surgeries that can be performed robotically, which in turn supports Intuitive Surgical’s opportunity to grow revenue in line with rising procedure volumes.
Representative product: da Vinci for gynecology
A representative example of Intuitive Surgical’s product footprint is its da Vinci gynecologic procedures portfolio. For gynecology patients, Intuitive Surgical outlines several types of operations that can be performed using the da Vinci system, including da Vinci hysterectomy for removal of the uterus, da Vinci pelvic organ prolapse surgery to correct supportive tissue issues, da Vinci myomectomy to remove fibroids, and da Vinci endometriosis resection to treat endometrial tissue growth outside the uterus. These procedures leverage the robotic system’s fine control and visualization to navigate complex anatomy through small incisions.
From a patient perspective, the potential advantages of da Vinci gynecologic procedures include shorter hospital stays, fewer transfusions, and quicker return to normal activities compared with traditional open surgery. However, Intuitive Surgical and medical providers also stress that any surgery carries risks, including possible injury to tissues or organs, bleeding, infection, and internal scarring that can cause lasting pain or dysfunction. The decision to undergo a da Vinci procedure is therefore made in consultation with physicians, who evaluate whether robotic-assisted surgery is appropriate given each patient’s diagnosis and overall health.
Closing stock paragraph
As of August 30, 2026, Intuitive Surgical stock trades at $372.60 on Nasdaq, set against a 52-week high of $603.88 and an earlier analyst price objective of $500, giving investors a clear numerical picture of how the current quote compares with both historical peaks and selected forward-looking valuation benchmarks.
Fact box
Company: Intuitive Surgical Inc.
ISIN: US46120E6023
Ticker: ISRG
Exchange: Nasdaq
Price (as of August 30, 2026, close): $372.60 USD
Sector / Industry: Health care equipment
Index membership: S&P 500
